Comparative Pharmacology
Head-to-head clinical analysis: ERYTHRO STATIN versus ERYTHROCIN STEARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHRO STATIN versus ERYTHROCIN STEARATE.
ERYTHRO-STATIN vs ERYTHROCIN STEARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythro-statin is a combination of erythromycin, a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and a statin (HMG-CoA reductase inhibitor) that inhibits cholesterol synthesis. Synergistic effects on inflammation and atherosclerosis are hypothesized.
Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It may also act as a motilin receptor agonist, stimulating gastrointestinal motility.
200 mg intravenously once daily.
250-500 mg orally every 6 hours for mild to moderate infections; up to 4 g/day for severe infections.
None Documented
None Documented
2.0-3.5 hours in adults with normal renal function. Extended to 5-8 hours in patients with severe renal impairment (CrCl <30 mL/min).
1.5-2 hours in adults; prolonged to 5-6 hours in severe hepatic impairment. In anuria, half-life not significantly affected.
Approximately 70-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. About 20-30% is eliminated unchanged in feces via biliary secretion.
Primarily biliary-fecal (90-95% as unchanged drug and metabolites); renal excretion accounts for 2-15%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic